ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None20232022202120202019 Date Title 28 November 2023 CEO Presentation to 2023 Annual General Meeting 28 November 2023 Mesoblast Chairman Message to 2023 AGM 27 November 2023 MSB Files for FDA Designations in Congenital Heart Disease 22 November 2023 Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial 15 November 2023 Mesoblast Corporate Presentation 31 October 2023 Quarterly Activities/Appendix 4C Cash Flow Report 30 October 2023 Annual Report to Shareholders 30 October 2023 Notice of Annual General Meeting and Proxy Form 30 October 2023 Appendix 4G and Corporate Governance Statement 16 October 2023 Notification of cessation of securities - MSB 16 October 2023 Notification regarding unquoted securities - MSB 29 September 2023 Final Director's Interest Notice 26 September 2023 Jane Bell Appointed Chair of Audit and Risk Committee 21 September 2023 Mesoblast Type A Meeting with FDA 31 August 2023 MSB Annual Financial Results and Operational Update 31 August 2023 Annual Financial Results Presentation 31 August 2023 Preliminary Final Report including Appendix 4E 29 August 2023 Mesoblast 2023 Full Year Financial Results Webcast 29 August 2023 Change in substantial holding 11 August 2023 Ceasing to be a substantial holder 10 August 2023 Ceasing to be a substantial holder 10 August 2023 Change in substantial holding 09 August 2023 Change in substantial holding 09 August 2023 Change in substantial holding 04 August 2023 Update on BLA for Graft Versus Host Disease 03 August 2023 Change in substantial holding 02 August 2023 Trading Halt 01 August 2023 Change in substantial holding 31 July 2023 Quarterly Activities/Appendix 4C Cash Flow Report 07 July 2023 Appendix 3G, Appendix 3H and Appendix 3Ys 13 June 2023 Change of Director's Interest Notice 05 June 2023 Mesoblast Director Appointed to Strategic Advisory Role 26 May 2023 MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023 Third Quarter Results Presentation 26 May 2023 Third Quarter Financial Results on Form 6-K 24 May 2023 Mesoblast Third Quarter Financial Results Webcast 03 May 2023 Becoming a substantial holder 03 May 2023 Change in substantial holding 01 May 2023 Cleansing Notice 28 April 2023 Application for quotation of securities - MSB 28 April 2023 Quarterly Activities/Appendix 4C Cash Flow Report 26 April 2023 Reinstatement to Official Quotation 26 April 2023 Proposed issue of securities - MSB 26 April 2023 Mesoblast Completes Private Placement 24 April 2023 Voluntary Suspension 20 April 2023 Trading Halt 20 April 2023 Pause in Trading 22 March 2023 FDA Schedules GvHD Pre-License Manufacturing Inspection 15 March 2023 Appendix 3G and Appendix 3H 08 March 2023 FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L 08 March 2023 Pause in Trading 03 March 2023 Prospectus for Warrants Related to Oaktree Facility 28 February 2023 DREAM HF Trial Published in JACC 28 February 2023 MSB Q2 Financial Results and Operational Highlights 28 February 2023 Second Quarter Results Presentation 28 February 2023 Half Yearly Report and Accounts 27 February 2023 Mesoblast Second Quarter Financial Results Webcast 17 February 2023 Remestemcel Clinical and Potency Studies Presented at Tandem 09 February 2023 FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP 01 February 2023 Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD 31 January 2023 Quarterly Activities/Appendix 4C Cash Flow Report 16 January 2023 Appendix 3G, Appendix 3H and Appendix 3Ys 10 January 2023 Biotech Showcase 2023 Presentation in San Francisco
